Health Care

Arcellx CEO Rami Elghandour’s recent insider buy—89,916 shares at $113.92—signals confidence in the pending Gilead deal, hinting at a potential post‑acquisition upside for investors.

Axsome COO buys RSUs amid price dip—inside look at insider confidence, long‑term plans and what it means for investors.

Q32 Bio insiders sell RSU‑triggered shares at $4.51; routine tax‑related sales keep the CEO, CFO and CSO’s long‑term stake strong amid a 13% monthly price climb.

Crystal Adam’s recent Tango stock sale signals disciplined risk‑management, not panic, as she’s building options for a bullish future. Investors should watch the Q4 earnings to gauge potential upside.

Insider sale of 75 Becton Dickinson shares by Chief Revenue Officer Michael Feld shows a routine, small‑scale trade—no red flag yet for BDX investors.

Insider buying at Thermo Fisher Scientific signals confidence in its mid‑growth outlook, boosting investor sentiment.

Thermo Fisher CFO’s 1,534‑share buy signals management’s confidence and a potential short‑term upside amid dividend hikes and positive market sentiment.

Farley Brian’s recent insider sale at Acadia Healthcare shows routine small‑scale divestment, not a red flag, and offers investors insight into executive liquidity needs and confidence amid steady earnings and moderate profitability.

Insider sale of IDEXX shares by EVP Hunt Nimrata shows routine rebalancing, not a confidence shift – a stable sign for investors in veterinary diagnostics.

Prime Medicine insider buys signal CEO confidence in a big biotech win – 1.3 M stock options, rising share price, and growing market sentiment show a promising next phase.